We discuss the critical role hydroxychloroquine plays in the management of lupus patients and suggest considering the psychosocial implications of the current pandemic on lupus care.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Systemic lupus erythematosus is a chronic remitting-relapsing autoimmune disease that affects multiple organ systems.
📊
Temel Bulgular & Veri:In this article we discuss aspects in the management of lupus patients that are particularly relevant during the current SARS-CoV-2 pandemic.
💡
Sonuç & Katkı:We discuss the critical role hydroxychloroquine plays in the management of lupus patients and suggest considering the psychosocial implications of the current pandemic on lupus care.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Abstract
Systemic lupus erythematosus is a chronic remitting-relapsing autoimmune disease that affects multiple organ systems. In this article we discuss aspects in the management of lupus patients that are particularly relevant during the current SARS-CoV-2 pandemic. We speculate that lupus patients might be more susceptible for a more severe COVID-19 disease course and emphasize the importance of maintaining remission in lupus patients. We discuss the critical role hydroxychloroquine plays in the management of lupus patients and suggest considering the psychosocial implications of the current pandemic on lupus care.
🔖
Bu Makaleye Atıf Yap
SAWALHA, A. H., MANZI, S. (2022). Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus. European Journal of Rheumatology, Cilt: 7 - Sayı: 2, 117–120. https://ajindex.com/articles/503155
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020
[Crossref] 2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020
[Crossref] 3. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep 2020
[Crossref] 4. Dhital R, Pandey RK, Poudel DR, Oladunjoye O, Paudel P, Karmacharya P. All-cause hospitalizations and mortality in systemic lupus erythematosus in the US: Results from a national inpatient database. Rheumatol Int 2020
[Crossref] 5. D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl. 2020 March 20. doi:10.1002/lt.25756. [Online ahead of print]. [Crossref] 6. Teruel M, Sawalha AH. Epigenetic variability in systemic lupus erythematosus: what we learned from genome-wide dna methylation studies. Curr Rheumatol Rep 2017
[Crossref] 7. Li Y, Gorelik G, Strickland FM, Richardson BC. Oxidative stress, T cell DNA methylation, and lupus. Arthritis Rheumatol 2014
[Crossref] 8. Sawalha AH, Zhao M, Coit P, Lu Q. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 2020
https://doi.org/10.1016/ j.clim.2020.108410. [Crossref] 9. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991
[Crossref] 10. Fessler BJ, Alarcon GS, McGwin G, Jr., Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005
[Crossref] 11. Pons-Estel GJ, Alarcón GS, McGwin G, Jr., Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009
[Crossref] 12. Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D. Identification of clinical and serological